Dronabinol Oral Solution
Dronabinol Oral Solution is an orally-administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol (THC), which may offer advantages over Dronabinol SG, including more consistent bioavailability, faster onset of action and more flexible dose titration.
|Drug||Indication||Preclinical||Phase 1||Phase 2/3||NDA||Approved|
|Fentanyl Sublingual Spray||BTCP in Opioid Tolerant Patients||
|Dronabinol SG (Generic Marinol®)||2nd Line CINV||
|Dronabinol Oral Solution||2nd Line CINV||
We submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in August 2014 for Dronabinol Oral Solution for anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.